Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the debt to assets ratio high or low?
The debt to assets ratio of 6.69% is 140% above its 5-year average of 2.78%, around the middle of its 5-year range (0.58%–18.07%).
As of the fiscal period ended Tuesday, June 30, 2026. 46.20% below its 12-month average of 12.44%.
Reported quarterly debt to assets ratio; no daily interpolation. Q2 FY2026 (2026-06-30): 6.69%.
DEBT TO ASSETS RATIO
6.69%
DEBT TO ASSETS RATIO AVG TTM
12.44%
DEBT TO ASSETS RATIO AVG 3Y
7.04%
DEBT TO ASSETS RATIO AVG 5Y
2.78%
DEBT TO ASSETS RATIO AVG 10Y
2.26%
DEBT TO ASSETS RATIO AVG 15Y
N/A
DEBT TO ASSETS RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
-46.20%
CURRENT VS 3Y AVG
-4.95%
CURRENT VS 5Y AVG
+140.43%
CURRENT VS 10Y AVG
+195.64%
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
0.09%
median of 870 covered companies
CURRENT VS SECTOR MEDIAN
+7337.17%
vs the sector median at left
Quantum BioPharma Ltd.
Market Cap
$20.99M
Debt to Assets Ratio
6.69%
TTM Avg
12.44%
3Y Avg
7.04%
5Y Avg
2.78%
Market Cap
$21.72M
Debt to Assets Ratio
0.02%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$22.22M
Debt to Assets Ratio
0.17%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$19.16M
Debt to Assets Ratio
0.08%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$22.88M
Debt to Assets Ratio
0.00%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$18.81M
Debt to Assets Ratio
0.00%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$18.80M
Debt to Assets Ratio
0.20%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | DEBT TO ASSETS RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Quantum BioPharma Ltd. (QNTM) | $20.99M | 6.69% | 12.44% | 7.04% | 2.78% |
| Modular Medical, Inc. (MODD)vs › | $21.72M | 0.02% | N/A | N/A | N/A |
| Aytu BioPharma, Inc. (AYTU)vs › | $22.22M | 0.17% | N/A | N/A | N/A |
| NextCure, Inc. (NXTC)vs › | $19.51M | 0.19% | N/A | N/A | N/A |
| LeonaBio, Inc. (LONA)vs › | $22.48M | 0.01% | N/A | N/A | N/A |
| Actuate Therapeutics Inc (ACTU)vs › | $19.16M | 0.08% | N/A | N/A | N/A |
| Rein Therapeutics Inc. (RNTX)vs › | $22.88M | 0.00% | N/A | N/A | N/A |
| Neuphoria Therapeutics Inc. (NEUP)vs › | $18.81M | 0.00% | N/A | N/A | N/A |
| P3 Health Partners Inc. (PIII)vs › | $18.80M | 0.20% | N/A | N/A | N/A |
| TherapeuticsMD, Inc. (TXMD)vs › | $23.61M | 0.15% | N/A | N/A | N/A |
Debt/Assets
6.7%
Debt/Equity
0.12
Current Ratio
1.20
Interest Coverage
-24.7x
Formula: Debt/Assets = Total Debt / Total Assets × 100
Debt/Assets vs Debt/Equity:
Industry context matters: Capital-intensive industries (utilities, real estate) typically have higher Debt/Assets ratios than tech companies.
Debt/Assets ratio shows what percentage of a company's assets are financed by debt. Compare the current value with the historical chart and peer group to understand leverage over time.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | DEBT TO ASSETS RATIO |
|---|---|
| 2026-06-30 | 6.69% |
| 2026-03-31 | 5.83% |
| 2025-12-31 | 16.81% |
| 2025-09-30 | 18.07% |
| 2025-06-30 | 14.81% |
| 2025-03-31 | 8.61% |
| 2024-12-31 | 4.82% |
| 2024-09-30 | 1.96% |
| 2024-06-30 | 4.10% |
| 2024-03-31 | 4.04% |
| 2023-12-31 | 1.94% |
| 2023-09-30 | 1.92% |
| 2023-06-30 | 1.95% |
| 2023-03-31 | 1.58% |
| 2022-12-31 | 1.34% |
| 2022-09-30 | 1.28% |
| 2022-06-30 | 0.99% |
| 2022-03-31 | 0.99% |
| 2021-12-31 | 0.88% |
| 2021-09-30 | 0.58% |
| 2021-06-30 | 0.60% |
| 2021-03-31 | 0.62% |
| 2020-12-31 | 1.22% |
| 2020-09-30 | 1.83% |
| 2020-06-30 | 3.86% |
| 2020-03-31 | 4.58% |
| 2019-12-31 | 3.68% |
| 2019-09-30 | 3.08% |
| 2019-06-30 | 3.00% |
| 2019-03-31 | 0.48% |
| 2018-12-31 | 0.00% |
| 2018-09-30 | 0.00% |
| 2018-06-30 | 0.00% |
| 2018-03-31 | 0.00% |
| 2017-11-30 | 270.37% |
| 2017-08-31 | 197.82% |
| 2017-05-31 | 169.65% |
| 2016-08-31 | 0.00% |
